Cytiva

Cytiva is working to address increasing demand for flexibility and component interchangeability.

Cytiva is transforming in the wake of COVID-19 – but what lessons can the wider biopharma industry take forward?

Digital technology, data analytics and continuous processing. The world of biopharma is changing rapidly.

We must never forget unmet needs when developing new medicines.

CGT developers: consider, at an early stage, how to produce your product at scale or you may run into problems with commercial manufacturing.

Higher productivity, lower hold times, lower costs… continuous processing for monoclonal antibodies could offer a number of advantages.

Digitalization means a more productive and adaptive plant through the application of analytics to leverage connectivity and data.

Rather than fearing the unknown, the concept of optionality can help you better manage it.

Now is the time to push bioprocess efficiencies even further...

The western world could be considered king of the biotech jungle, but eager biopharma tigers from the east are hungry for a piece of the action – and they are gaining ground. Can single-use technologies help them to catch up even faster? Jinghui Xu believes so.

Join us to discuss general trends in process intensification and see real-world examples of where we have implemented intensification strategies successfully.

In this webinar we will look in depth at the Xcellerex™ magnetic mixer, designed to deliver high performance for even the most challenging large-scale single-use mixing applications.

This webinar is a unique opportunity to gain exclusive insights into the world of oligonucleotide manufacturing. Stay ahead of the curve by learning about the latest trends in this dynamic field that can help you future-proof your manufacturing.

In this webinar, CPI will discuss its collaborative programs (Grand Challenges) and how they look to address the challenges posed by the innovations in oligonucleotide manufacturing.

Learn about Cytiva's catalogue of ready-to-use engineered AAVrep/cap sequences.

As more AAV-based gene therapies move towards the clinic, there is a growing need for scalable and cost-effective production processes that maintain virus quality.

The use of adenovirus-associated virus (AAV) vectors in gene therapy is growing.

Cell therapy logistics is challenged by complex processes, inefficiency, and lack of flexibility to accommodate manufacturing, clinic, and patient needs